Barclays PLC Trims Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Barclays PLC lowered its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 93.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,248 shares of the company's stock after selling 434,704 shares during the quarter. Barclays PLC owned approximately 0.06% of PMV Pharmaceuticals worth $45,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in PMV Pharmaceuticals in the 2nd quarter worth about $101,000. Cubist Systematic Strategies LLC boosted its stake in shares of PMV Pharmaceuticals by 570.8% in the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company's stock worth $113,000 after acquiring an additional 59,452 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of PMV Pharmaceuticals by 36.1% during the third quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company's stock worth $527,000 after purchasing an additional 93,809 shares in the last quarter. M&T Bank Corp raised its stake in PMV Pharmaceuticals by 54.6% in the 3rd quarter. M&T Bank Corp now owns 399,548 shares of the company's stock valued at $596,000 after purchasing an additional 141,064 shares during the last quarter. Finally, BML Capital Management LLC lifted its holdings in PMV Pharmaceuticals by 29.0% in the 3rd quarter. BML Capital Management LLC now owns 1,688,772 shares of the company's stock valued at $2,516,000 after purchasing an additional 379,375 shares in the last quarter. 90.20% of the stock is owned by institutional investors and hedge funds.

PMV Pharmaceuticals Price Performance

PMV Pharmaceuticals stock traded down $0.02 during trading on Friday, reaching $1.37. 42,172 shares of the company were exchanged, compared to its average volume of 160,027. The stock's 50 day simple moving average is $1.52 and its two-hundred day simple moving average is $1.55. The company has a market capitalization of $70.90 million, a P/E ratio of -1.37 and a beta of 1.46. PMV Pharmaceuticals, Inc. has a 52-week low of $1.32 and a 52-week high of $2.26.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). As a group, equities analysts forecast that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Oppenheimer raised shares of PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 target price for the company in a report on Friday, November 8th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, PMV Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $5.50.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.